Low‐molecular weight inhibitors of the alternative complement pathway
A Schubart, S Flohr, T Junt, J Eder - Immunological Reviews, 2023 - Wiley Online Library
Dysregulation of the alternative complement pathway predisposes individuals to a number
of diseases. It can either be evoked by genetic alterations in or by stabilizing antibodies to …
of diseases. It can either be evoked by genetic alterations in or by stabilizing antibodies to …
Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases
MS Meuleman, A Grunenwald, S Chauvet - Seminars in Immunology, 2022 - Elsevier
Abstract C3 glomerulopathy (C3G) is a rare and complex kidney disease that primarily
affects young adults. Renal outcomes remain poor in the absence of specific treatment. C3G …
affects young adults. Renal outcomes remain poor in the absence of specific treatment. C3G …
Recognition of tumor-associated antigens and immune subtypes in glioma for mRNA vaccine development
S Ma, Y Ba, H Ji, F Wang, J Du, S Hu - Frontiers in Immunology, 2021 - frontiersin.org
Background Although mRNA vaccines have been efficient for combating a variety of tumors,
their effectiveness against glioma remains unclear. There is growing evidence that …
their effectiveness against glioma remains unclear. There is growing evidence that …
[HTML][HTML] Is complement the main accomplice in IgA nephropathy? From initial observations to potential complement-targeted therapies
MB Le Stang, PJ Gleeson, MR Daha, RC Monteiro… - Molecular …, 2021 - Elsevier
Abstract IgA Nephropathy (IgAN) is the main cause of primary glomerulonephritis, globally.
This disease is associated with a wide range of clinical presentations, variable prognosis …
This disease is associated with a wide range of clinical presentations, variable prognosis …
Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice
O Kamala, TH Malik, TM Hallam, TE Cox… - Frontiers in …, 2021 - frontiersin.org
C3 glomerulopathy (C3G) is associated with dysregulation of the alternative pathway (AP) of
complement and treatment options remain inadequate. Factor H (FH) is a potent regulator of …
complement and treatment options remain inadequate. Factor H (FH) is a potent regulator of …
Contribution of animal models to the mechanistic understanding of Alternative Pathway and Amplification Loop (AP/AL)‐driven Complement‐mediated Diseases
BG Gibson, TE Cox, KJ Marchbank - Immunological Reviews, 2023 - Wiley Online Library
This review aimed to capture the key findings that animal models have provided around the
role of the alternative pathway and amplification loop (AP/AL) in disease. Animal models …
role of the alternative pathway and amplification loop (AP/AL) in disease. Animal models …
Development of a C3 humanized rat as a new model for evaluating novel C3 inhibitors
JY Chen, L Zhang, M Yang, ED Hughes… - Journal of Innate …, 2023 - karger.com
Introduction: C3 is central for all complement activation pathways, thus making it an
attractive therapeutic target. Many C3-targeted agents are under extensive development …
attractive therapeutic target. Many C3-targeted agents are under extensive development …
[引用][C] Development of a C3 Humanized Rat as a New Model for Evaluating Novel C3 Inhibitors
JYCLZ Maojing, YED Hughesb, ZT Freemanb… - 2023 - europepmc.org
Introduction: C3 is central for all complement activation pathways, thus making it an
attractive therapeutic target. Many C3-targeted agents are under extensive development …
attractive therapeutic target. Many C3-targeted agents are under extensive development …